| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 09/11/2001 | US6288037 C-terminally modified pentapeptides containing valine and aspartic acid |
| 09/11/2001 | US6288036 Bradykinin type peptides |
| 09/11/2001 | US6288029 Template assembled synthetic peptide effective to treat respiratory system disorders |
| 09/11/2001 | US6287836 Histidine kinase from Streptococcus pneumoniae and compositions therecontaining |
| 09/11/2001 | US6287786 Nucleic acid molecules encoding a new mammalian protein and to the use of these molecules in the characterization, diagnosis, and treatment of conditions such as disorders associated with cell proliferation, lipid metabolism and transport. |
| 09/11/2001 | US6287599 Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles |
| 09/11/2001 | CA2230936C 5-azabicyclo(3.1.0)hexylalkyl-2-piperidones and -glutarimides as neurokinin receptor antagonists |
| 09/11/2001 | CA2200742C Quinoxaline derivatives useful in therapy |
| 09/11/2001 | CA2195119C Formulations and methods for providing prolonged local anesthesia |
| 09/11/2001 | CA2164866C Treatment of neuromuscular disorders and conditions with different botulinum serotype |
| 09/11/2001 | CA2087091C Excitatory amino acid antagonists |
| 09/11/2001 | CA2067187C Central nervous system activator and taste enhancing food additive |
| 09/11/2001 | CA2057578C 1,4-disubstituted piperazines, process for their preparation and pharmaceutical compositions containing them |
| 09/11/2001 | CA2037099C Crystalline salt of 4-(di-n-propyl) amino-6-aminocarbonyl-1,3,4,5-tetrahydrobenz ¢cd! indole |
| 09/11/2001 | CA2031570C Substituted cyclohexenes as central nervous system agents |
| 09/07/2001 | WO2001064907A2 Lipid metabolism enzymes |
| 09/07/2001 | WO2001064896A2 Human enzyme molecules |
| 09/07/2001 | WO2001064884A2 G12l, a gene associated with the thermal response |
| 09/07/2001 | WO2001064879A2 G-proteins coupled receptor related polypeptides |
| 09/07/2001 | WO2001064877A2 Human schizophrenia gene |
| 09/07/2001 | WO2001064876A2 Human schizophrenia gene |
| 09/07/2001 | WO2001064837A2 β NETRIN AND USES THEREOF |
| 09/07/2001 | WO2001064737A1 Novel human ulip/crmp protein and use thereof in diagnosis and treatment of cancers and paraneoplastic neurological syndromes |
| 09/07/2001 | WO2001064703A1 Serine/threonine phosphatase polynucleotides, polypeptides, and antibodies |
| 09/07/2001 | WO2001064691A1 Il-8 receptor antagonists |
| 09/07/2001 | WO2001064681A2 3-(pyrolyllactone)-2-indolinone compounds as kinase inhibitors |
| 09/07/2001 | WO2001064679A1 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases |
| 09/07/2001 | WO2001064677A1 Novel imidazotriazinones and the use thereof |
| 09/07/2001 | WO2001064673A1 Flavone derivatives, preparation method and use as medicines |
| 09/07/2001 | WO2001064671A2 Haloimidazole derivatives and their use as muscarinic m3 and serotoninergic 5-ht4 receptors |
| 09/07/2001 | WO2001064670A1 Novel cyclic amide derivatives |
| 09/07/2001 | WO2001064669A1 Pyrazole ether derivatives as anti-inflammatory/analgesic agents |
| 09/07/2001 | WO2001064668A2 1,3-dihydro-2h-indol-2-one, and their use as v1b or both v1b and v1a arginine-vasopressin ligand receptors |
| 09/07/2001 | WO2001064666A1 Oxygen-containing heterocyclic compounds |
| 09/07/2001 | WO2001064661A1 Antioxidants |
| 09/07/2001 | WO2001064645A2 Derivatives of quinoline as alpha-2 antagonists |
| 09/07/2001 | WO2001064639A2 Pde iv inhibiting amides, compositions and pharmaceutical use |
| 09/07/2001 | WO2001064637A1 2-oxo-1-pyrrolidine derivatives, process for preparing them and their uses |
| 09/07/2001 | WO2001064634A1 Pharmaceutical compositions containing azetidine derivatives, novel azetidine derivatives and preparation thereof |
| 09/07/2001 | WO2001064633A1 Pharmaceutical compositions containing 3-amino-azetidine derivatives, novel derivatives and preparation thereof |
| 09/07/2001 | WO2001064632A1 Azetidine derivatives, preparation thereof and pharmaceutical compositions containing same |
| 09/07/2001 | WO2001064631A2 Derives de polyfluoroalkylimidazole et leur utilisation en tant qu'antagonistes des recepteur muscariniques m3 et serotoniques 5-ht4 |
| 09/07/2001 | WO2001064280A1 Method and apparatus for transcutaneous infusion of carbon dioxide for local relief of pain and other ailments |
| 09/07/2001 | WO2001064250A1 Remedies for malignant tumor-concomitant neurosis and azoor or analogous diseases thereof |
| 09/07/2001 | WO2001064247A2 Method of treating cancer with anti-neurotrophin agents |
| 09/07/2001 | WO2001064240A2 Methods for promoting production of myelin by schwann cells |
| 09/07/2001 | WO2001064239A1 A method of treatment |
| 09/07/2001 | WO2001064228A1 Method for producing a bioactive substance from blood serum |
| 09/07/2001 | WO2001064220A1 Use of trimetazidine to inhibit acyl-coa acetyl transferase |
| 09/07/2001 | WO2001064214A2 Compositions and methods for the treatment of inflammatory diseases using topoisomerase inhibitors |
| 09/07/2001 | WO2001064208A1 Il-8 receptor antagonists |
| 09/07/2001 | WO2001064201A2 Restricting reinstatement of drug use |
| 09/07/2001 | WO2001064165A2 Il-8 receptor antagonists |
| 09/07/2001 | WO2001064149A1 Improved transdermal drug patch |
| 09/07/2001 | WO2001064057A1 Novel pharmaceutical or dietetic mushroom-based compositions |
| 09/07/2001 | WO2001019823A3 Substituted pyridino pentaazamacrocyle complexes having superoxide dismutase activity |
| 09/07/2001 | WO2001016289A3 Zymogen activation system |
| 09/07/2001 | WO2001016135A3 Reverse-turn mimetics and methods relating thereto |
| 09/07/2001 | WO2001013901A3 A pharmaceutical delivery system for vitamin c and vitamin e and use of a combination of vitamin c and e for preventing or treating conditions involving oxidative stress |
| 09/07/2001 | WO2001010383A3 Caspase inhibitors and uses thereof |
| 09/07/2001 | WO2000075107A3 Bradykinin receptor antagonists |
| 09/07/2001 | WO2000062765A3 ESTROGEN RECEPTOR-β LIGANDS |
| 09/07/2001 | WO2000054763A3 Pharmaceutical compositions comprising polymorphic forms of dehydroepiandrosterone |
| 09/07/2001 | WO2000047618A3 HUMAN β-SECRETASE ENZYME, INHIBITORS AND THEIR COMPOSITIONS AND USES |
| 09/07/2001 | WO2000047603A9 16-hydroxyestratrienes as selective estrogens |
| 09/07/2001 | WO2000002912A3 Disintegrin homologs |
| 09/07/2001 | CA2401989A1 A method of treatment |
| 09/07/2001 | CA2401834A1 Novel imidazotriazinones and the use thereof |
| 09/07/2001 | CA2401716A1 Methods for promoting production of myelin by schwann cells |
| 09/07/2001 | CA2401697A1 Pyrazole ether derivatives as anti-inflammatory/analgesic agents |
| 09/07/2001 | CA2401670A1 Human enzyme molecules |
| 09/07/2001 | CA2401667A1 Pde iv inhibiting amides, compositions and pharmaceutical use |
| 09/07/2001 | CA2401660A1 Lipid metabolism enzymes |
| 09/07/2001 | CA2401659A1 Il-8 receptor antagonists |
| 09/07/2001 | CA2401489A1 Oxygen-containing heterocyclic compounds |
| 09/07/2001 | CA2401453A1 G-proteins coupled receptor related polypeptides |
| 09/07/2001 | CA2401340A1 Compositions and methods for the treatment of inflammatory disease using topoisomerase inhibitors |
| 09/07/2001 | CA2401173A1 G12l, a gene associated with the thermal response |
| 09/07/2001 | CA2400679A1 Human schizophrenia gene |
| 09/07/2001 | CA2400657A1 Derivatives of quinoline as alpha-2 antagonists |
| 09/07/2001 | CA2400649A1 3-(pyrolyllactone)-2-indolinone compounds as kinase inhibitors |
| 09/07/2001 | CA2400595A1 Human schizophrenia gene |
| 09/07/2001 | CA2400375A1 Method and apparatus for transcutaneous infusion of carbon dioxide for local relief of pain and other ailments |
| 09/07/2001 | CA2400138A1 Pharmaceutical compositions containing 3-amino-azetidine derivatives, novel derivatives and preparation thereof |
| 09/07/2001 | CA2400116A1 Azetidine derivatives, preparation thereof and pharmaceutical compositions containing same |
| 09/07/2001 | CA2397502A1 Serine/threonine phosphatase polynucleotides, polypeptides, and antibodies |
| 09/07/2001 | CA2372185A1 Novel pharmaceutical or dietetic mushroom-based compositions |
| 09/06/2001 | US20010020095 High affinity for D4 receptors; treatment of schizophrenia, other psychoses, anxiety disorders, depression, alcohol abuse, impulse control disorders, aggression |
| 09/06/2001 | US20010020040 Hyperforin derivatives, use thereof and formulations containing them |
| 09/06/2001 | US20010020036 Synergistic mixtures |
| 09/06/2001 | US20010020032 Olanzapine |
| 09/06/2001 | US20010020028 Agents for treating neurodegenerative disorders |
| 09/06/2001 | US20010020027 Using 1-(4-(1-(4-fluorophenyl)-1H-indole-3-yl)-1-butyl spiro(isobenzofuran-1(3H,4-piperidine) |
| 09/06/2001 | US20010020024 Opioid analgesics |
| 09/06/2001 | US20010020022 2{3-[4-(2-t-butyl-6-trifluoromethylpyridin-4-yl) piperazin-1-yl] propylmercapto} pyrimidin-4-ol-fumarate |
| 09/06/2001 | US20010020021 Metalloprotease inhibitor |
| 09/06/2001 | US20010020013 Polymerase inhibitors |
| 09/06/2001 | US20010020006 Dipeptidyl peptidase; antidiabetic agents |
| 09/06/2001 | US20010019724 Carotenoid formulations, comprising a mixture of beta-carotene, lycopene and lutein |
| 09/06/2001 | DE10010067A1 New 2-phenyl-imidazo (5,1-f) (1,2,4) triazin-4-one derivatives, are phosphodiesterase inhibitors useful for treating cardiovascular, cerebrovascular or urogenital disorders |